Oncolytics Biotech is conducting clinical trials in multiple indications with the objective of developing REOLYSIN® as a human cancer therapeutic. Oncolytics’ clinical development program emphasizes three pillars: chemotherapy combinations to trigger selective tumor lysis; immuno-therapy combinations to produce adaptive immune responses; and immune modulator (IMiD) combinations to facilitate innate immune responses. Oncolytics is currently planning its first registration study in breast cancer, as well as studies in combination with checkpoint inhibitors and IMID/targeted therapies in solid and hematological malignancies.

Legacy Studies

Trial Number Phase Trial Name Indication Status
REO 022
Phase I Intravenous Administration of REOLYSIN in Combination with FOLFIRI and Bevacizumab (Avastin®) in FOLFIRI-Naïve Patients with Mutant Metastatic Colorectal Cancer Colorectal Cancer Ongoing

REOLYSIN® is currently available in a clinical trial setting only. It has not been approved in any jurisdiction and is not available for purchase. The Company, its directors, officers, employees and affiliates have no influence over the inclusion of a patient in a clinical trial. Should a patient’s physician determine that he or she may be a suitable clinical trial candidate, they must contact a participating center. Contact information, as well as inclusion and exclusion criteria, for both US and international participating centers can be found at www.clinicaltrials.gov for studies with a US component.